EU competition law and IP rights

Introductory materials

In order to reward and encourage investment and innovation, intellectual property law grants owners of intangible property exclusive exploitation rights. Intellectual property right (IPR) holders therefore have, in principle, the right to control access to (and charge others for use of) their IPRs as well as pursue enforcement of these rights through the courts where otherwise unauthorised use has occurred.

At the same time, exercising such rights may run up against competition law requirements which, broadly speaking, aim to promote open markets and curtail abuse of market power—and, in the EU context, ensure the integration and integrity of the Single Market by removing impediments to cross border trade.

Practice Note: EU Competition law and intellectual property considers the extent to which competition law applies to the following questions that have arisen in relation to the ownership and protection of IPRs:

  1. What competition law considerations apply to patenting practices such as the decision to seek (or not seek) IPR protection and an IPR owner’s conduct before the regulatory authorities?

  2. What competition law rules apply to licensing of IPRs?

  3. When

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

Powered by Lexis+®
Latest EU Law News

MedTech Europe leads industry call for EU to provide medical device regulatory relief by early 2026

MedTech Europe, together with 35 national associations, has urged the European Commission to take swift action on regulatory challenges affecting the medical device and diagnostic sectors. While EU officials are already collecting evidence to support future reforms of the medical device and in vitro diagnostic regulations, which are meant to simplify and improve efficiency, the signatories of the open letter argue that immediate relief is also essential. They call for a combination of short-term measures alongside longer-term legislative reforms. In particular, the letter asks for an implementing act to standardize the work of notified bodies, pilot projects for regulatory pathways covering orphan, pediatric, and breakthrough devices, and a targeted delay of re-certification requirements for certain products. According to MedTech Europe, harmonizing rules for notified bodies would help reduce duplication, speed up assessments, and ease the overall regulatory burden. The proposed postponement of re-certification deadlines is seen as necessary to avoid bottlenecks that could disrupt the supply of devices ahead of 2028. Looking further ahead, the associations want amendments to both MDR and IVDR that reflect the specific needs of each sector, alongside the creation of a single governance structure to oversee notified bodies and the CE-marking system, which they consider vital to the future of European medical technology regulation.

View EU Law by content type :

Popular documents